Captor Therapeutics®

Q3 2024 Results

All images by Piotr Piatek

Legal notice

This document and the information contained herein (unless otherwise indicated) have been prepared by Captor Therapeutics S.A. (the “Issuer”) solely for informational purposes. For this notice, the presentation that follows shall mean and include the slides that follow, the oral presentation of the slides by the Issuer or any person on behalf of the Issuer, any question-and-answer session that follows the oral presentation, hard copies of this document, and any materials distributed at, or in connection with the presentation (collectively, the “Presentation”). By attending the meeting at which the Presentation is made, or by reading the Presentation, you will be deemed to have (i) agreed to all of the following restrictions and made the following undertakings and (ii) acknowledged that you understand the legal and regulatory sanctions attached to the misuse, disclosure or improper circulation of the Presentation.

The information contained in this Presentation may not be reproduced or redistributed in any way, in whole or in part, to any other person without the prior written consent of the Issuer. This Presentation does not purport to contain all the information that may be required by the recipient to assess the Issuer or its securities. The Issuer prepared this Presentation based on the information which it has and from sources believed to be reliable. To the extent available, the industry, market, and competitive position data contained in this Presentation come from official or third-party sources. There is no guarantee of the accuracy or completeness of such data.

This Presentation contains neither a complete nor a comprehensive financial or commercial analysis of the Issuer, nor does it present its position or prospects in a complete or comprehensive manner. The Issuer has prepared the Presentation with due care, however certain inconsistencies or omissions might have appeared in it. Therefore it is recommended that any person who intends to undertake any investment decision regarding any security issued by the Issuer shall only rely on information released as an official communication (i.e., current/periodic reports) in accordance with the legal and regulatory provisions.

This Presentation may contain certain forward-looking statements, forecasts, estimates, projections, and opinions ("Forward-looking Statements"). By their nature, Forward-looking Statements involve known and unknown risks, uncertainties, assumptions, and other factors because they relate to events and depend on circumstances that will occur in the future whether or not outside the control of the Issuer. No representation is made or will be made that any Forward-looking Statements will be achieved or will prove to be correct. Actual future results and operations could vary materially from the Forward-looking Statements. Similarly, no representation is given that the assumptions disclosed in this Presentation upon which Forward-looking Statements may be based are reasonable. The recipient acknowledges that circumstances may change and the contents of this Presentation may become outdated as a result. The assumptions included herein do not constitute profit forecasts or profit estimates.

No warranties or representations can be made as to the comprehensiveness or reliability of the information contained in this Presentation. Neither the Issuer nor its directors, managers, advisers or representatives of such persons shall bear any liability that might arise in connection with any use of this Presentation. Furthermore, no information contained herein constitutes an obligation or representation of the Issuer, its managers or directors, its shareholders, subsidiary undertakings, advisers or representatives of such persons.
Data contained in this Presentation is valid as of the day of its preparation. Consequently, this Presentation will not be subject to changes, updates or modifications to account for events which might occur after this day.

This Presentation does not constitute or form part of, and should not be construed as, an offer to sell or issue, or the solicitation of an offer to purchase, subscribe to, or acquire the Issuer or the Issuer´s securities, or an inducement to enter into investment activity in any jurisdiction in which such offer, solicitation, inducement or sale would be unlawful before registration, exemption from registration or qualification under the securities laws of such jurisdiction. No part of this Presentation, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. This presentation is not for publication, release, or distribution in any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction nor should it be taken or transmitted into such jurisdiction.

Fully owned pipeline

Programme	Primary Target	Indications	Modality
CT-01	GSPT1	**Hepatocellular carcinoma**, Lung cancer, NET tumours	MG
CT-02B†	NEK7	Neuroinflammation (Parkinson's Disease, ALS, MS)	MG
CT-02S‡	NEK7	Systemic autoimmunity	MG
CT-03	MCL-1	Liquid & solid tumours	BIFD
CT-05	PKCϴ	Autoimmunity, Oncology, Transplantation, Metabolism	BIFD
	New target projects	Autoimmunity, Cancer	MG BIFD
	New E3 ligase degraders	Autoimmunity, Cancer	MG BIFD



†CT-02B - Brain-penetrant
‡CT-02S - Systemic

Preclinical stage includes IND-enabling studies, **BIFD – Bi-functional Degrader; **MG** – Molecular Glue*

Assumed stage at the end of 2025

Captor Therapeutics®

CT-01: First-in-Class GSPT1 Targeted Degrader for Hepatocellular Carcinoma (HCC)

CT-01: Multi-target GSPT1, NEK7 & SALL4 degrader



GSPT1 degradation leads to an Integrated Stress Response and induction of apoptosis in HCC cells

SALL4 is expressed in fetal liver, silenced in adults, but often re-expressed in HCC and correlates with poor prognosis

NEK7 degradation leads to reduction of IL-1β production – a well-establish pro-carcinogenic factor. Reduction of IL-1β levels enables activation of the immune response

CT-01 is a pro-drug activated by an enzyme present at high levels in the liver, lungs and certain gastrointestinal tumors

A unique degradation profile combined with target tissue pro-drug activation for liver, lung and neuroendocrine cancers

Captor Therapeutics®

CT-01: Progress to the clinic

- *In vitro* and *in vivo* pharmacology studies ✓
- Drug Substance synthesis optimization and manufacture in large scale ✓
- DMPK studies ✓
- Preliminary toxicology studies in 2 animal species ✓
- Toxicology studies under GLP (GLP Tox) ✓
- Drug Substance GMP manufacture ✓
- Drug Product – capsule preparation ✓
- CTIS (Clinical Trial Information System) package preparation and submission ✓
- Clinical Trial Application Assessment 

Laboratory compliant with GCLP (Good Clinical Laboratory Practice) standards

(Research Quality Association (RQA) Good Clinical Laboratory Practice (GCLP) Version 2: December 2012)

- Laboratory prepared for clinical analyses to evaluate the biological/pharmacological effect of a drug candidate
- Advanced analytical instruments, software supporting laboratory work and sample management
- Internal quality system to ensure appropriate standards and compliance with EMA regulations of clinical sample testing and bioanalytical methods
- Detailed validation plans for both analytical methods (WB, qRT-PCR) and computerized systems to confirm that all methods and systems used are appropriate for the project objectives
- Appropriately trained personnel are qualified to perform tests in accordance with the GCLP standard

CT-03: First-in-Class MCL-1 Degraders for Liquid & Solid tumors

CT-03: MCL-1 – a critical pathway of cancer resistance



MCL-1 is one of the most amplified proteins in cancer†

A critical resistance mechanism in haematological and solid tumors‡

Degradation or inhibition of MCL-1 protein directly attenuates tumors *in vivo* as monotherapy & sensitizes tumors for other therapies

Adequate ablation of MCL-1 requires rapid and sustained action & high target coverage

Use of inhibitors causes accumulation of MCL-1

Degraders have a different mode of action, without accumulation of MCL-1

Degradation of ~70% of MCL-1 induces apoptosis, while inhibitors require almost 100% of target coverage and cause accumulation of the MCL-1

This, together, with optimized clearance expands the therapeutic window from the perspective of toxicity

1. https://gco.iarc.fr/today/en/
2. Semin Cancer Biol. 2006 16(4):253-64
3. Cell Death Dis 2018 9(2): 19
4. Breast Cancer Res. 2016 18(1): 125
5. Int J Mol Sci. 2019 20(3): 5999
6. Cell Death Dis. 2022 13(1): 63
7. Colorectal Dis 2022 24(11): 1295-1307
8. Ann Fam Med. 2016 14(3): 215-20
9. Exp Hematol Oncol. 2020 Jun 19;9:14
10. Hum Pathol. 2004 Sep;35(9):1095-100
11. ACS Key Statistics for AML, CLL, Lymphoma
12. Curr Treat Options Oncol. 2020 Jun 29;21(8):66
13. Int J Mol Sci. 2024 Jan 27;25(3):1589
14. Blood Rev. 2020 Nov;44:100672
15. Leukemia. 2013 Jun;27(6):1381-90

†Front Oncol. 2023 Jul 31;13:1226289
‡Apoptosis. 2023 Feb;28(1-2):20-38

Status: CT-03

Bifunctional Degrader

- **Degradation profile**
  - Selective first-in-class MCL-1 degrader
- **Strong differentiation from MCL-1 inhibitors**
  - Totally different pharmacology from MCL-1 inhibitors
  - No accumulation of MCL-1 protein
  - No cardiotoxicity observations in MTD, DRF in NHPs
- **Initial indications**
  - Hematological cancers
  - Solid tumors
- **Development activities / expected milestone**
  - Efficacy proven *ex vivo* & *in vivo*
  - Candidate selection made: CPT-03p (pro-drug)
  - Toxicological studies planned
    - Dose range finding (DRF)
    - 28-day GLP tox studies
- **IND submission H2 2025**
- **Regular updates held with large pharma**

CT-02: First-in-Class NEK7 Degraders for Autoimmune & Neurodegenerative Diseases

CT-02: Vast market potential for inflammasome modulators

Allergy
Asthma

Fibrotic diseases

Lupus nephritis

Psoriasis



Neuroinflammation
(AD, PD, MS, ALS)

Myocardial infarction
Diabetic cardiomyopathy

Inflammatory Bowel Disease

Gout
Rheumatoid Arthritis

NEK7 degradation inhibits inflammasome formation and hence the production of inflammatory cytokines, leading to the reduction of symptoms of immune-related diseases.

Recent publications demonstrate the potential role of CNS inflammasome in weight loss

Growing interest in degraders in inflammation (Kymera)

Two series of potent NEK7 degraders:

CPT-635r - systemic therapy for the treatment of **autoimmune disorders**

CPT-732r - therapy of inflammatory **neurodegenerative disorders (NDDs)**

Significant market opportunities for Captor's NEK7 degraders

CT-02S
CPT-635r

Systemic diseases

The possibility of using NEK7 degraders in combination with available therapeutics to manage comorbidities

Three vast therapeutic areas:

Obesity Metabolic Disorders	Autoimmune Diseases	Cardiovascular Diseases
16% living with obesity worldwide[5]	5-10% of global population[6]	19.8M deaths in 2022 due to CVD[7]
Global market size (2030):		
$100B[1]	$10.9B[2]	$124.9B[3]



CT-02B
CPT-732r

Neurodegeneration driven by inflammation

There is growing evidence of the role of pathological activation of innate immunity in the pathogenesis of NDDs; limited treatment strategies available; potential to inhibit disease progression via NEK7 degradation

PD: 8.5M patients living worldwide (2019)[5]

AD: 6.7M patients in US (2023)[10]

HD: Global prevalence estimated at 4.88 per 100,000[8]

ALS: Global prevalence estimated at 4.42 per 100,000[9]

NDD market size is estimated at $4.9B[4] (2030)

1. https://www.goldmansachs.com/intelligence/pages/anti-obesity-drug-market.html
2. https://www.databridgemarketresearch.com/reports/global-autoimmune-disease-treatment-market
3. https://www.researchandmarkets.com/report/cardiovascular
4. https://www.researchandmarkets.com/report/neurodegenerative-disease-drug
5. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
6. J Autoimmun. 2010 May;34(3):J168-77.
7. J Am Coll Cardiol. 2023 Dec 19;82(25):2350-2473
8. https://pubmed.ncbi.nlm.nih.gov/36161673/
9. https://pubmed.ncbi.nlm.nih.gov/31797084/
10. https://alz-journals.onlinelibrary.wiley.com/

Status: CT-02S & CT-02B

Studies on the most active diastereoisomers of the lead compounds have continued:

- Interspecies efficacy, safety, and selectivity of NEK7 degraders
- Pharmacokinetic (PK) properties and blood-brain barrier penetration of both compounds evaluated in a mouse model
- In discussion with potential partners and to support expansion of studies in additional disease animal models

Results Highlights

Key points from the financial results in Q3 2024

- Increase in revenues from collaborations from PLN **6,7M** to PLN**12,9 M**
- Decrease in grant revenues from PLN **12,3M** to PLN **3,7M**
- Narrowing loss from PLN **59,1M** to PLN **29,7M** due to focus on lead projects, timing of expenditure on CT-01 costs, and management expenses
- Reduced operational cash outflow from PLN **34,9M** in Q3 2023 to PLN **23,6M** in Q3 2024

Balance sheet and cash position

Consolidated statement of financial position (PLN, M)



Cash position



Available funding secured
(PLN M; as of September 30, 2024):

Total : PLN M 104,6*

- PLN M 48,8 cash
- PLN M 55,8 available grants (NCBR; ABM)

*** Amount includes grant awarded for phasing in CT-03 and CT-01 project.**

R&D costs in Q3 2024**:**

Total : PLN M 38,3

Net Operational Cash Outflow in Q3 2024**:**

Total : PLN M 23,6

Current (September 2024) guidance indicates cash runway until Q3 2025

Captor Therapeutics®

Captor Therapeutics®

Captor Therapeutics S.A.
ul. Duńska 11
54-427 Wrocław, Poland

Captor Therapeutics GmbH
Hegenheimermattweg 167A
4123 Allschwil, Switzerland

Contact: investor.relations@captortherapeutics.com